Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
29/09/2026 12:10
BRIEF-Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate Sept 29 (Reuters) - Unicycive Therapeutics Inc UNCY.O:
UNICYCIVE THERAPEUTICS ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR OXYLANTHANUM CARBONATE
UNICYCIVE THERAPEUTICS - FDA ACCEPTANCE OF NDA EXPECTED WITHIN 30 DAYS; NEW PDUFA DATE IN 6 MONTHS
UNICYCIVE THERAPEUTICS - NDA RESUBMISSION INCLUDES CMC DATA FROM NEW MANUFACTURING VENDOR
UNICYCIVE THERAPEUTICS - FDA INSPECTION OF ORIGINAL MANUFACTURING VENDOR ASSIGNED BUT NOT COMPLETED AS OF SEPT 29, 2026
Source text: ID:nGNX2LQpgd
Further company coverage: UNCY.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss